TY - STD TI - Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer.Theranostics. 2012;2:4181–501. ID - ref1 ER - TY - STD TI - Garayoa EG, Schweinsberg C, Maes V, Brans L., Blauenstein P, Tourwe DA, Schibli R, Schubiger P A. Influence of the molecular charge on the biodistribution of bombesin analogue labeled with the [99mTc(CO)3]-core. Bioconjug Chem. 2008;19:2409–2416. ID - ref2 ER - TY - STD TI - Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427. ID - ref3 ER - TY - STD TI - Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi J C, Maecke HR. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumors. Eur J Nucl Med Mol Imaging. 2007;34:1198–1208. ID - ref4 ER - TY - STD TI - Karra SR, Gali RH, Katti KV, Hoffman TJ, Higginbotham C, Sieckman GL, Volkert WA. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjug Chem. 1999;10:254–260. ID - ref5 ER - TY - STD TI - Retzloff LB, Heinzke L, Figureoa SD, Sublett SV, Ma L Sieckman, GL Rold, TL Santos, I. Hoffman TJ, Smith CJ. Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2]conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res. 2010;30:19–30. ID - ref6 ER - TY - STD TI - Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004;24:357–397. ID - ref7 ER - TY - STD TI - Parry JJ, Andrews R, Roger BE. Micro-PET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175–183. ID - ref8 ER - TY - STD TI - De K, Banerjee I, Misra M. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation. Amino Acids. 2015;47:1135–1153. ID - ref9 ER - TY - STD TI - Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF. Preclinical comparison of (111)In-labeled DTPA or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 2002;43:1650–1656. ID - ref10 ER - TY - STD TI - Reubi JC. Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med. 2002;29:855–862. ID - ref11 ER - TY - STD TI - Carlesso FN, Fuscaldi LL, Araujo RS, Teixeira CS, Oliveira MC, Fernandes SOA, Cassali GD, Reis DC, Barros ALB, Cardoso VN. Evaluation of 99mTc-HYNIC-βAla-Bombesin(7-14) as an agent for pancreas tumor detection in mice. Braz J Med Biol Res. 2015;48:923–928. ID - ref12 ER - TY - STD TI - Jamous M, Tamma ML, Gourni E, Waser B, Reubi JC, Maecke HR, Mansi R. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists. Nucl Med Biol. 2014;41:464–470. ID - ref13 ER - TY - STD TI - de Barros, AL, Mota LG., Ferreira CA, Oliveira MC, Goes AM, Cardoso VN. Bombesin derivative radiolabeled with technetium-99m as agent for tumor identification. Bioorg Med Chem Lett. 2010;20:6182–6184. ID - ref14 ER - TY - STD TI - Valverde IE, Vomstein S, Mindt TL. Toward the optimization of bombesin-based radiotracers for tumor targeting. J Med Chem 2016;59:3867–3877. ID - ref15 ER - TY - STD TI - Ranyuk E, Cauchon N, Klarskov K, Guérin B, Van JEL. Phthalocyanine-peptide conjugates: receptor-targeting bifunctional agents for imaging and photodynamic therapy. J Med Chem. 2013;56:1520−1534. ID - ref16 ER - TY - STD TI - Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC, Maina T. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005;48:100−110. ID - ref17 ER - TY - STD TI - Good S, Walter MA, Waser B., Wang XJ, Muller-Brand J., Behe M P, Reubi JC, Maecke HR. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging. 2008;35:1868−1877. ID - ref18 ER - TY - STD TI - Shirmardi SP, Gandomkar M, Mazidi M. Synthesis and evaluation of a new bombesin analog labeled with 99mTc as a GRP receptor imaging agent. J Radioanal Nucl Chem. 2011;288:327−335. ID - ref19 ER - TY - STD TI - Pujatti PB, Foster JM, Chantelle CF, Hudson D, Burnet JC, Pasqualoto KFM, Mengatti J, Mather SJ, de Araújo EB, Sosabowski JK. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models. Appl Rad Isotopes. 2015;96:91−101. ID - ref20 ER - TY - STD TI - Liu Y, Hu X, Liu H, Bu L, Ma X, Cheng K, Li Tian JM, Zhang H, Cheng ZA. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J Nucl Med. 2013;54:2132–2138. ID - ref21 ER - TY - STD TI - Okarvi SM, Jammaz I Al. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics. Nucl Med Biol. 2012;39:795–804. ID - ref22 ER - TY - STD TI - Ferreiraa C de A, Fuscaldib LL, Townsendc DM, Rubellod D, de Barrosb ALB. Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed. Pharmacotherapy. 2017;87:58–72. ID - ref23 ER - TY - STD TI - De K, Bhowmik A, Behera A, Banerjee I, Ghosh M K, Misra M. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy. J Pept Sci. 2012;18:720–730. ID - ref24 ER - TY - STD TI - De K, Banerjee I, Sinha S, Ganguly S. Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor. Peptides. 2017;89:17–34. ID - ref25 ER - TY - STD TI - Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Claude J, Maecke HR. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imag. 2007;34:1198–1208. ID - ref26 ER - TY - STD TI - Gandomkar M, Najafi R, Shafiei Mazidi M, Ebrahimi SES. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-NaI3, Thr8]-octreotide as a new analogue in the detection of somatostatinreceptor-positive tumors. Nucl Med Biol. 2007;34:651–657. ID - ref27 ER - TY - STD TI - Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS. Micro-PET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004;45:1390–1397. ID - ref28 ER - TY - STD TI - Akla B, Monteil J, Paraf F, Sturtz F, Rigaud MA. A new peritoneal carcinomatosis model in cyclosporine immunosuppressed rats. Anticancer Res. 2003;23:3761–3766. ID - ref29 ER - TY - STD TI - Fingert HJ., Treiman A, Pardee AB. Transplantation of human or rodent tumors into Cyclosporine - treated mice: a feasible model for studies of tumor biology and chemotherapy. Proc Natl Acad Sci. 1984;81:7927–7931. ID - ref30 ER - TY - STD TI - Min K, Ji B, Zhao M, Ji T, Chen B, Fang X, Ma, Q. Development of a radiolabeled peptide-based probe targeting MT1-MMP for breast cancer detection. Plos One. 2015;10:e0139471. ID - ref31 ER - TY - STD TI - Iorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, El Ashry D, Lippman MA. A new mouse model for the study of human breast cancer metastasis. Plos. One. 2012;7:e47995. ID - ref32 ER - TY - STD TI - Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadimayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F. Combination of gastrin-releasing peptide antagonist ith cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell cycle. 2012;11:2518–2525. ID - ref33 ER - TY - STD TI - Park HJ, Kim SR, Kim MK, Choi KS, Jang HO, Yun I l, Bae SK, Bae M K. Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo. Cancer Lett. 2011;312:117–127. ID - ref34 ER - TY - STD TI - Gao D, Bambang I F, Putti TC, Lee YK, Richardson DR, Zhang D. ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK. Lab Invest. 2012;92:200–213. ID - ref35 ER - TY - STD TI - Marsden CG, Wright MJ, Carrier L, Moroz K, Pochampally R, Rowan BG. A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies. BMC Cancer. 2012;12:10. ID - ref36 ER - TY - STD TI - Bella RL, Garcia-Garayoa E, Bahler M, Blauenstein P, Schibli Conrath RP, Tourwe D, Schubiger PA. A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem. 2002;13:599–604. ID - ref37 ER - TY - STD TI - Branco de Barros AL. Radiolabeled peptides as imaging probes for cancer diagnosis. J Mol Pharm Org Process Res. 2014;2:e115. ID - ref38 ER - TY - STD TI - Schroeder RPJ, van Weerden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods. 2009;48:200–204. ID - ref39 ER - TY - STD TI - Garcia Garaypoa E, Schweinsberg C, Maes V, Brans Blauenstein LP, Tourwe DA, Schibli RP. August Schubiger. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem. 2008;19:2409–2416. ID - ref40 ER - TY - STD TI - Smith CJ, Volkert WA, Hoffman T. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. J Nucl Med Biol 2005;32:733–740. ID - ref41 ER -